FDA Approves AbbVie's DECNUPAZ for Ultra-Rare Blood Cancer, Marking First ADC in Oncology
ABBV sits 18% above its 52-week low of $181.73.
Summary
The FDA has approved AbbVie's DECNUPAZ for blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive blood cancer. This approval is significant as DECNUPAZ is AbbVie's first antibody-drug conjugate (ADC) approved for blood cancer, expanding its oncology portfolio into a new modality. While BPDCN is rare, it addresses a high unmet medical need and offers a new treatment option, notably as the only outpatient-initiated ADC for this condition. This positive regulatory development follows a mixed period for AbbVie, including a recent FDA decline for a different product in April, but also strong Q1 earnings and positive data for other key drugs.
At the time of this announcement, ABBV was trading at $214.19 on NYSE in the Life Sciences sector, with a market capitalization of approximately $380.6B. The 52-week trading range was $181.73 to $244.81. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.